Trastuzumab, pertuzumab, and eribulin mesylate versus trastuzumab, pertuzumab, and a taxane as a first-line or second-line treatment for HER2-positive, locally advanced or metastatic breast cancer: study protocol for a randomized controlled, non-inferiority, phase III trial in Japan (JBCRG-M06/EMERALD).

Yamashita T, Masuda N, Saji S, Araki K, Ito Y, Takano T, Takahashi M, Tsurutani J, Koizumi K, Kitada M, Kojima Y, Sagara Y, Tada H, Iwasa T, Kadoya T, Iwatani T, Hasegawa H, Morita S, Ohno S

Open source

DOI
10.1186/s13063-020-04341-y
Published
2020 May 7
Container
Trials
Publisher
figshare
Open access
yes

Credibility signals

uncertain Score 61/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1186/s13063-020-04341-y,
  title = {Trastuzumab, pertuzumab, and eribulin mesylate versus trastuzumab, pertuzumab, and a taxane as a first-line or second-line treatment for HER2-positive, locally advanced or metastatic breast cancer: study protocol for a randomized controlled, non-inferiority, phase III trial in Japan (JBCRG-M06/EMERALD).},
  author = {Yamashita T and Masuda N and Saji S and Araki K and Ito Y and Takano T and Takahashi M and Tsurutani J and Koizumi K and Kitada M and Kojima Y and Sagara Y and Tada H and Iwasa T and Kadoya T and Iwatani T and Hasegawa H and Morita S and Ohno S},
  year = {2020},
  journal = {Trials},
  doi = {10.1186/s13063-020-04341-y},
  url = {https://doi.org/10.1186/s13063-020-04341-y}
}

RIS

TY  - JOUR
TI  - Trastuzumab, pertuzumab, and eribulin mesylate versus trastuzumab, pertuzumab, and a taxane as a first-line or second-line treatment for HER2-positive, locally advanced or metastatic breast cancer: study protocol for a randomized controlled, non-inferiority, phase III trial in Japan (JBCRG-M06/EMERALD).
AU  - Yamashita T
AU  - Masuda N
AU  - Saji S
AU  - Araki K
AU  - Ito Y
AU  - Takano T
AU  - Takahashi M
AU  - Tsurutani J
AU  - Koizumi K
AU  - Kitada M
AU  - Kojima Y
AU  - Sagara Y
AU  - Tada H
AU  - Iwasa T
AU  - Kadoya T
AU  - Iwatani T
AU  - Hasegawa H
AU  - Morita S
AU  - Ohno S
PY  - 2020
JO  - Trials
DO  - 10.1186/s13063-020-04341-y
UR  - https://doi.org/10.1186/s13063-020-04341-y
ER  -

APA

T, Y., N, M., S, S., K, A., Y, I., T, T., M, T., J, T., K, K., M, K., Y, K., Y, S., H, T., T, I., T, K., T, I., H, H., S, M., & S, O. (2020). Trastuzumab, pertuzumab, and eribulin mesylate versus trastuzumab, pertuzumab, and a taxane as a first-line or second-line treatment for HER2-positive, locally advanced or metastatic breast cancer: study protocol for a randomized controlled, non-inferiority, phase III trial in Japan (JBCRG-M06/EMERALD).. Trials. https://doi.org/10.1186/s13063-020-04341-y

Source records